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Abstract--Taking as models the polyamine toxin fraction FTX from the funnel-web spider venom, and the guanidinium oiety 
of guanethidine, a series of azaalkane-l,~o-diguanidinium salts were obtained. Some of them blocked ion fluxes through the 
neuronal nicotinic receptors for acetylcholine (nAChR). The blockade was exerted at submicromolar concentrations, suggesting a 
highly selective interaction with the nAChR. In fact, the active compounds on the nAChR ion channel did not recognize the 
voltage-dependent Na + or Ca 2+ channels of bovine adrenal chromaffin cells. Therefore, these compounds may be useful tools to 
clarify the functions of nAChR receptors in the central and peripheral nervous ystems. Copyright © 1996 Elsevier Science Ltd 
Introduction 
Mammalian nicotinic receptors for acetylcholine 
(nAChR) considerably differ in structure and function. 
Those mediating contraction at the skeletal muscle 
end-plate have a subunit composition (~)2 133'6 in 
developing muscle and (~)2 [3~ in mature muscle. 
Those present in neurons exhibit a much higher diver- 
sity and are constructed of combinations of ~ (a2-a7) 
and 13 (132-134) subunits. 1 Compared with muscle 
nAChR, little is known about functional aspects of 
neuronal nAChR in the brain. Peripherally, nAChR 
mediate the transmission of nerve impulses at sympa- 
thetic and parasympathetic ganglia and the release of 
catecholamines from adrenal medullary chromaffin 
cells. 2 Nicotinic receptors in bovine chromaffin cells are 
made up of 53 and 57 subunits and, therefore, belong to 
the neuronal subtypes of nAChR? 
Central nervous system nAChR have been implicated 
in the physiological regulation of human cognition, 4 
blood pressure, and heart rate, 5 as well as in neuro- 
psychiatric diseases including schizophrenia, ~ 
movement disorders, 7'~ Parkinson's disease, 9'~° and 
analgesiaJ ~ Despite their growing importance, there 
are few ligands and drugs to distinguish between the 
multiple neuronal nAChR subtypes. 5 These new drugs 
will help to clarify their physiological role, and may 
eventually lead to novel therapeutic strategies to treat 
those neuropsychiatric disorders. In designing the 
novel, highly potent, neuronal nAChR blockers 
reported here, two principal pieces of evidence were 
initially considered. One relates to the guanidinium 
moiety of guanethidine and the other to the 
polyamines. 
In a recent study, we tried to separate pharmacologic- 
ally various Ca 2~ entry pathways in bovine chromaffin 
cells stimulated with the selective agonist of nAChR 
1,1-dimethyl-4-phenylpiperazinium iodide (DMPP), or 
with high K + depolarizing solutions. We found that 
guanethidine, a potent blocker of noradrenaline r lease 
from sympathetic nerve terminals j2 and from 
chromaffin cells ~3 separated the K* and the DMPP 
responses. Thus, guanethidine fully blocked the 45Ca2+ 
uptake induced by DMPP, but left intact the 
K+-evoked response. 14In this study the hypothesis was 
raised that guanethidine could be a blocker of some of 
the subtypes of the high-threshold Ca 2~ channels 
described in bovine chromaffin cells. ~ However, the 
fact that the drug did not block the K~-evoked Ca 2÷ 
uptake prompted us to consider the early suggestion of 
Jaanus et alJ 3 that a direct blockade of nAChR could 
explain the inhibition by guanethidine of 45Ca2~ uptake 
into cells challenged with DMPP. This was the 
rationale for taking the guanidinium moiety present in 
the molecule of guanethidine as a model to design 
novel blockers for neuronal nAChR. 
The second piece of evidence considered comes from 
the observation that sFTX blocks a subcomponent of
the whole-cell Ba 2+ current through Ca 2+ channels in 
bovine chromaffin cellsJ 5 sFTX is a synthetic analogue 
of a polyamine toxin present in the venom of the 
funnel-web spider Agelenopsis aperta, which blocks 
P-type voltage-dependent Ca 2+ channels in neur- 
ones. j6'~7 These aliphatic polyamines include spermine, 
spermidine, putrescine, argiotoxin-636, and philanto- 
toxins. They are known to inhibit various ionic channel 
subtypes, including the glutamatergic and the nAChR 
ion channels, t~ 
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F igure  1. Molecular structure of the polyamine toxin fraction FTX 
from the funnel-web spider venom, and of guanethidine. 
The presence of terminal amino or guanidinium 
groups, and the increase in the length of the polyamine 
chain enhance the inhibitory polyamine effects on 
glutamate responses. '9'2° In this study we attempted to 
test the hypothesis that the introduction of two 
terminal guanidinium groups and amino groups, as well 
as the increasing length of the polyamine chain, could 
affect the Ca 2+ entry pathways in depolarized bovine 
adrenal chromaffin cells. Although some of the synthe- 
tized molecules partially inhibited Ca 2+ entry through 
Ca 2+ channels, other molecules exhibited a particularly 
high efficacy in blocking Ca 2+ entry induced by nAChR 
activation. Thus, we came across with a highly potent, 
novel class of nAChR blockers whose synthesis and 
pharmacological properties are reported here. 
Chemistry 
Several alkanediguanidinium salts were obtained 
exploring analogues of spider toxins FTX 21 (Fig. 1). 
The preparation (Fig. 2) was performed by reaction of 
the corresponding diamines 1 with S-methylisothiourea 
sulfate 2, yielding the guanidinium salt 3 with loss of 
mercaptan} 2 Related compounds have been described 
as fungicides 23-25 being 3C 26 described in a patent. 
Similarly, related structures have been described as 
microbicides 27, being 3t `28 and 3i 29 patented with that 
use. In the course of a research project on sympathetic 
nervous system blocking agents related to guanethi- 
dine, 3g was also described. 3° Some other related 
compounds had been described as anion complexing 
agents. 31 
CH3 H2N~N H 
. 
NH 2 H2N'-- ~ 
1 2 NH 3 H2SO 4 
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Figure 2. Synthesis ofalkanediguanidinium salt~. 
Results and Discussion 
Effects of alkanediguanidinium compounds on 4SEa2÷ 
uptake into chromaffin cells stimulated with high K + 
or DMPP 
The entry of 45Ca2+ through Ca 2+ channels was stimu- 
lated by direct depolarization of bovine chromaffin 
cells with high K +, or by indirect depolarization with 
the nAChR agonist DMPP. Concentrations of K ÷ (70 
mM) and DMPP (100 laM) producing similar incre- 
ments of 45Ca2+ entry were selected, t4
Table 1 summarizes the results obtained with the 10 
compounds studied at the concentration of 10 ~tM. 
Overall, the compounds were much more efficacious in 
blocking DMPP- than K+-induced 45Ca2+ entry. 
Compounds a, f, g, and j did not affect the K + signal. 
Compounds b, e, and i inhibited the K + effects by 10% 
or less. Compound c blocked 45Ca 2+ uptake by 15% 
and compounds d and h by about 30%. 45Ca2+ uptake 
evoked by DMPP was unaffected by compound g. 
Compounds a (12%), and h (21%) caused a small 
blockade. Compounds b, i, and j approximately halved 
the DMPP signal. Finally, compounds c, d, e, and f 
inhibited by over 90% 45Ca2+ uptake. 
The blocking effects of the DMPP response seemed to 
correlate well with the length of the aliphatic chain 
separating the two terminal guanidinium moieties. 
Thus, compound a (four - -CH2- -  groups) inhibited by 
12% the DMPP signal, compound b (seven --CH2 
groups) by 53%, and compounds c (eight - -CH2- -  
groups), d (nine - -CH2- -  groups), e (10 - -CH2- -  
groups), and f (12 - -CH2- -  groups) inhibited 45Ca2+ 
uptake by 98, 100, 90, and 91% respectively. A similar 
picture seemed to be true for compounds g (no 
blockade), h (21% blockade), i (47% blockade) and j 
(61% blockade). It seems that a minimum length of the 
molecule is required to occupy its binding site on the 
nAChR and to inhibit the effect of DMPP. From these 
experiments, it is not possible, however, to define the 
Table 1. Effects of alkanediguanidinium compounds on 45Ca2+ 
uptake into chromaffin cells stimulated with high K + or DMPP (see 
Biological methods for details) 
% Inhibition 
Compound n 70 mM K ÷ 100 ~M DMPP 
a 9 0 12+5 
b 12 7.8+11 52.8+7 
e 9 15.4 + 2.5 98.3 +_ 0.5 
d 6 31.8 + 2.5 100 
e 9 10.5 +5.2 90.2+3.1 
f 9 0 90.7_+4 
g 9 0 0 
h 12 31.5 +4.6 20.9+4.7 
i 12 3.8 + 8.4 46.7 + 8.6 
j 12 0 61.1 +6.2 
Data represent the percentage of inhibition of 45Ca2+ uptake by 10 
rtM of each compound. They are means +SEM of the number of 
culture wells shown in n. DMPP, 1,1-dimethyl-4-phenylpiperazinium 
iodide. 
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competitive or allosteric nature of the interaction on 
the nAChR between these compounds and DMPP. 
To define further the nature of the effects of these 
compounds on the nAChR, additional studies on 
4SCa2+ uptake and ionic currents were performed. For 
this purpose, compound e which affected little the 
K+-evoked 45Ca 2+ uptake and inhibited by over 90% 
the DMPP signal, was selected. 
Concentration-dependent effects of compound e on 
4SCa2 + uptake induced by DMPP 
Figure 3(A) shows the 45Ca2+ taken up by unstimulated 
cells (basal) and by chromaffin cells stimulated with 
DMPP (100 laM for 60 s) or high K + (70 mM for 60 s), 
in the absence and presence of 10 ~tM of compound e. 
Compound e did not affect the basal 4SCa2+ taken up 
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by cells. The increase in 45Ca2+ uptake induced by 
DMPP was fully blocked by 10 ~tM of compound e, but 
the K+-evoked increase in 45Ca2+ entry was unaffected. 
Figure 3(B) shows a full concentration-response curve 
on the effects of compound e on DMPP-induced 45Ca2+ 
uptake. Compound e inhibited the DMPP signal along 
a wide range of concentrations (more than 3 log units). 
Its calculated IC50 was 20 nM, suggesting that the 
compound exhibits a high potency to block the 
nAChR-mediated signals. 
Effects of compound e on ion currents through the 
nAChR 
Since these derivatives appeared to be rather active in 
blocking 45Ca 2+ uptake induced by DMPP, and because 
high K + and DMPP are both capable of opening Ca 2+ 
channels in chromaffin cells, it seemed that these 
compounds would have a direct effect on the nicotinic 
receptor. We tested this possibility by using the more 
direct approach of measuring DMPP currents with the 
patch-clamp technique under the whole-cell config- 
uration. 
Figure 4 shows the time course of the current elicited 
by 250 ms pulses of 100 ~tM DMPP, applied at 30 s 
intervals to a voltage-clamped chromaffin cell. The 
application of the compound immediately reduced the 
nAChR current o figures below 5%. The blockade was 
maintained along five subsequent DMPP pulses, but 
was quickly reversed upon removal of compound e 
from the cell superfusion system. The reintroduction f
the compound 7 min later produced a similar blockade 
that was fully reversed upon its washout. 
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Figure 3. (A) 4~Ca2+ uptake into cultured bovine chromaffin cells. 
45Ca2+ taken up by cells in basal conditions was determined after 
incubation of the cells for 1 min in a normal Krebs-HEPES solution 
containing radiotracer Ca 2+ (see Biological methods). Evoked Ca 2+ 
uptake was studied by exposing the cells for 60 s to 100 taM DMPP 
or 70 mM K +. Dashed columns how 45Ca2+ uptake in the presence 
of 10 ~tM of compound e, added 10 min before. Data are means 
+ SEM of nine wells from three different cell cultures. (B) Concen- 
tration-response curve for compound e, to block 45Ca2+ uptake into 
chromaffin cells stimulated with DMPP. Experimental design as 
above. Data are means +SEM of 4-5 triplicate experiments from 
different cell batches. 
Ion channel selectivity of compound e 
To test whether compound e selectively blocked the 
nAChR current, the following experiment was carried 
out. A cell was voltage-clamped at -80 mV and at 30 s 
intervals a pair of separate stimuli were applied. The 
first stimulus consisted of the application of 100 ~M 
DMPP for 250 ms (inward current through the 
nAChR); then, 2 s later, a depolarizing test pulse to 0 
mV and 50 ms duration was given (inward currents 
through voltage-dependent Na + and Ca 2+ channels). 
These paired stimuli were repeatedly given before, 
during and after the application of compound e (10 
~tM) [see protocol on top of Figure 5(A)]. The initial 
IDMpp peak elicited (ca. 2400 pA) was reduced to 
around 100 pA in the presence of the compound. In 
contrast, neither I~, (first peak of the current traces 
shown in the right part of panel A) nor lc, [plateau of 
the current traces in right part of Fig. 5(A)] were 
affected by compound e. In the presence of the 
compound, the residual IDMpp current left unblocked 
was around 10%, while over 90% of Ic, remained intact 
[Fig. 5(B)]. 
In conclusion, the alkanediguanidinium compounds 
synthetized act as blockers of ion fluxes through the 
neuronal nAChR. This blockade is exerted at 
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nanomolar concentrations, suggesting a highly selective 
interaction with nAChR. In fact, the voltage-dependent 
Na + and Ca 2+ channels are not recognized by these 
compounds. The alkanediguanidinium compounds 
might recognize selective subtypes of neuronal nAChR, 
although it remains to be elucidated if skeletal muscle 
nAChR are also targetted by these compounds. These 
compounds may become useful tools to clarify the 
functions of such receptors in the central and 
peripheral nervous systems. Eventually, further struc- 
tural modulation of these molecules might lead to 
compounds useful in the treatment of neuropsychiatric 
diseases in which nAChR have been implicated. 
Chemistry 
Experimental 
Melting points were determined on a Bfichi SMP-20 
and are uncorrected. IR spectra (KBr) were recorded 
using a Perkin-Elmer 599B spectrophotometer. ~H 
NMR spectra were obtained on a Varian Unity 300 
(300 MHz) spectrometer. Chemical shifts are expressed 
in ppm downfield from tetramethylsilane. Elemental 
analyses were carried out on a Heraeus rapid CHN 
analyser. All chemicals were commercially purchased 
and purified before using when necessary. CAUTION: 
ethylmercaptan is evolved. 
Preparation of alkanediguanidinium salts 
General procedure. A mixture of the corresponding 
diamine (3 mmol) and S-methylisothiourea sulfate (2.5 
g, 9 retool) were dissolved in water (2 mL). The 
mixture was heated to reflux for the time indicated in 
each case. Then, the mixture was allowed to stand at 
room temperature for 24 h, and a white precipitate 
appeared. The solid was filtered, washed with water 
(2 x 1 mL) and acetone (2 x 1 mL) being crystallized 
from water. 
Butane-l,4-diguanidinium sulfate (3a). According to 
the general procedure, starting from butane- 
1,4-diamine (0.264 g), the mixture was heated for 5 h, 
and after the usual work up, 3a was isolated as white 
prisms (500 mg, 62%), mp 299-303 °C (dec). IR (v, 
cm '): 3343, 3132, 2940, 1679, 1626, 1481, 1452, 1383, 
1074, 749. 'H NMR (CF3COOD): 3.40 (m, 4H); 1.84 
(m, 4H). Anal. calcd for C6Hl~N604S'l/2H20: C, 25.79; 
H, 6.36; N, 30.09. Found: C, 26.12; H, 6.55; N, 29.61. 
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Figure 4. Time course for the blocking effects and washout of 10 pM of compound e on the peak current induced by 250 ms pulses of DMPP 
(IoMpP) in a voltage-clamped bovine chromaffin cell. The holding potential of the cell was maintained at -80 mV. DMPP pulses were applied at 
30 s intervals. Insets on top of the figure labeled with letters A, B, C, and D show original traces obtained at the points indicated on the time 
course curve. 
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Heptane-l,7-diguanidinium sulfate (3b). According 
to the general procedure, starting from heptane- 
1,7-diamine (0.39 g), the mixture was heated for 7 h, 
and after the usual work up, 3b was isolated as white 
prisms (460 rag, 49%), mp 314-318 °C (dec). IR (v, 
cm t): 3374, 3159, 2938, 1662, 1086, 726. ~H NMR 
(CF3COOD): 2.77 (t, 4H, J=7.1 Hz); 1.19 (bs, 4H); 
0.93 (bs, 6H). Anal. calcd for CqH24N604S: C, 34.60; H, 
7.74; N, 26.90; S, 10.26. Found: C, 34.40; H, 7.97; N, 
27.10; S. 10.50. 
Octane-l,8-diguanidinium sulfate (3c). According to 
the general procedure, starting from octane- 
1,8-diamine (0.432 g), the mixture was heated for 5 h, 
and after the usual work up, 3c was isolated as white 
prisms (583 rag, 60%), mp 314-317 °C. IR (v, cm ~): 
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Figure 5. The protocol used to simultaneously record IDMpp, Ic'~ and 
1N~, in voltage-clamped chromaffin cells is shown on the top part of 
the figure. Part (A) shows the current recorded after brief (250 ms) 
applications of a solution containing 100 laM DMPP (IDMPP), applied 
at 30 s intervals to cells held at a membrane potential of -80  mV in 
an individual cell. They represent the control IDMpp and that in the 
presence of 10 gM of compound e. The right panel shows the effects 
of compound e on 1N. and lc, evoked by 50 ms depolarizing pulses to 
0 mV applied from a holding potential of -80  mV. Part (B) shows 
averaged ata on the blockade of 10 gM compound e on 1DMpp. IN, 
and lc, in bovine chromaffin cells. Data correspond to the mean 
+SEM of the number of cells shown in parentheses on top of each 
bar. 
3359, 3168, 2934, 1644, 1475, 1382, 1107. IH NMR 
(CF3COOD): 3.36 (t, 4H); 1.74 (m, 4H); 1.47 (bs, 8H). 
Anal. calcd for CIoH26N604S'l/2H20: C, 35.81; H, 8.11; 
N, 25.05. Found: C, 36.18; H, 8.07; N, 24.77. 
Nonane-l,9-diguanidinium sulfate (3d). According to 
the general procedure, starting from nonane- 
1,9-diamine (0.474 g), the mixture was heated for 5 h, 
and after the usual work up, 3d was isolated as white 
prisms (560 rag, 55%), mp 302-306 °C (dec). IR (v, 
cm 1): 3364, 3168, 2934, 1644, 1118, 1056. IH NMR 
(CF3COOD): 2.75 (bs, 4H); 1.19 (bs, 4H); 0.88 (bs, 
10H). Anal. calcd for C.H2sN604: C, 37.80; H, 8.36; N, 
24.05. Found: C, 37.75; H, 8.59; N, 24.31. 
Decane-l,10-diguanidinium sulfate (3e). A solution 
of S-methylisothiourea sulfate (0.550 g, 2 mmol) in 
water (2 mL) was added to a solution of decane- 
1,10-diamine (0.344 g, 2 mmol) in acetonitrile (1 mL). 
The mixture was heated to reflux for 18 h, and a preci- 
pitate appeared. Water (3 mL) was added, and the 
mixture was allowed to cool. The solid was filtered and 
washed with acetone (2 mL) and diethyl ether (10 mL) 
to give 3e (509 rag, 72%), mp 262-266°C. IR (v, 
cm-1): 3361, 3146, 2930, 2856, 1640, 1112, 1078. IH 
NMR (CF3COOD): 2.80 (t, 4H); 1.20 (bt, 4H); 0.90 
(bs, 12H). Anal. calcd for CI2H30N6OaS: C, 40.66; H, 
8.53; N, 23.71; S, 9.04. Found: C, 40.79; H, 8.80; N, 
23.81; S, 9.32. 
Dodecane-l,12-diguanidinium sulfate (3f). According 
to the general procedure, starting from dodecane- 
1,12-diamine (0.6 g), the mixture was heated for 10 h, 
and after the usual work up 3f was isolated as white 
prisms (600 rag, 52%), mp 258-262 °C. IR (v, cm J): 
3165, 2923, 2854, 1685, 1631, 1116, 1079. JH NMR 
(CF3COOD): 2.74 (t, 4H); 1.18 (m, 4H); 0.84 (m, 
16H). Anal. calcd for C14H34N604S: C, 43.96; H, 8.59; 
N, 21.97; S. 8.38. Found: C, 44.18; H, 8.87; N, 21.78; S, 
8.12. 
Preparation of azaalkanediguanidinium salts 
General procedure. A mixture of the corresponding 
polyamine (9 mmol) and S-methylisothiourea sulfate 
(2.78 g, 10 mmol) in dry acetonitrile (25 mL) was 
heated to reflux under argon for the time indicated. 
After cooling to room temperature, the precipitate was 
filtered, washed with acetonitrile (10 mL), and crystal- 
lized from water. 
3-Azapentane-l,5-diguanidinium sulfate (3g). Accord- 
ing to the general procedure, starting from 
N-(2-aminoethyl)ethane-l,2-diamine (0.927 g), the 
mixture was heated for 17 h, and after the usual work 
up, 3g was isolated as white prisms (2.37 g, 87%), mp 
307-310 °C. IR (v, cm-1): 3167, 2826, 1648, 1460, 1346, 
1291, 1264, 1109, 895, 618. 1H NMR (D20) 3.08 (t, 
4H); 2.57 (t, 4H). Anal. calcd for C6HwN704S 'H20:  C, 
23.75; H, 6.98; N, 32.32; S, 10.57. Found: C, 23.75; H, 
7.50; N, 32.98; S, 10.41. 
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3-Azahexane-l,6-diguanidinium sulfate (3h). Accord- 
ing to the general procedure, starting from N-(2- 
aminoethyl)propane-l,3-diamine (1.05 g), the mixture 
was heated for 19 h, and after the usual work up, 3h 
was isolated as white prisms (2.62 g, 78%), mp 192 °C 
(dec). IR (v, cm-1): 3383, 2528, 2358, 2324, 2083, 1645, 
1525, 1480, 1367, 1255, 1124, 862, 762, 664, 617. 1H 
NMR (DzO) 3.53 (t, 2H); 3.17 (m, 4H); 2.18 (t, 2H); 
1.94 (m, 2H). Anal. calcd for C7H2~NTO7.sS1.5: C, 22.45; 
H, 6.46; N, 26.18; S, 12.84. Found: C, 22.71; H, 7.27; N, 
26.03; S, 13.13. 
4-Azaheptane-l,7-diguanidinium sulfate (3i). Accord- 
ing to the general procedure, starting from 3,3'-diami- 
nopropylamine (1.18 g), the mixture was heated for 22 
h, and after the usual work up, 3i was crystallized from 
EtOH:H20 (1:5, 2.32 g, 65%), mp 280-283 °C. IR (v, 
cm-~): 3356, 3183, 2959, 2806, 1648, 1457, 1124, 618. 
tH NMR (D20) 3.08 (t, 4H); 2.90 (t, 4H); 1.77 (m, 
4H). Anal. calcd for CsH28N7OsSl.5: C, 24.11; H, 7.08; 
N, 24.60; S, 12.07. Found: C, 24.96; H, 7.10; N, 24.25; 
S, 11.43. 
4,7-Diazadecane-l,10-diguanidinium sulfate (3j). Ac- 
cording to the general procedure, starting from 
N,N'-bis(3-aminopropyl)ethane-l,2-diamine (1.57 g), 
the mixture was heated for 17 h, and after the usual 
work up, 3j was crystallized from EtOH:H20 (1:5, 
2.72 g, 62%), mp 288-290 °C. IR (v, cm-~): 3132, 2732, 
2468, 1691, 1641, 1521, 1480, 1403, 1383, 1068, 968, 
795, 746, 626. 1H NMR (CF3COOD): 3.86 (m, 4H); 
3.50 (m, 8H); 2.36-2.26 (m, 4H). Anal. calcd for 
C10H30NsOsS2"2H20: C, 24.48; H, 6.98; N, 22.84. 
Found: C, 25.14; H, 7.32; N, 22.28. 
Biological methods 
Isolation and culture of bovine chromaffin cells. Bo- 
vine adrenal medullary chromaffin cells were isolated 
following standard methods 32 with some modifica- 
tions. 33 Cells were suspended in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 5% 
foetal calf serum, 10 jaM cytosine arabinoside, 10 jaM 
fluorodeoxyuridine, 50 IU mL -1 penicillin and 50 jag 
mL -1 streptomycin. Cells were plated at a density of 
5x 105 cells/well in 24-multiwell Costar plates for 
45Ca2+ uptake studies and were used 1-5 days after 
plating. For whole-cell current experiments, cells were 
plated on glass coverslips at a density of 25 x 103 cells 
mL -1. Medium was replaced after 24 h and then after 
2-3 days. 
Measurements of 45Ca2+ uptake. 45Ca 2+ uptake studies 
were carried out in cells after 1-5 days in culture. 
Before the experiment, cells were washed twice with 
0.5 mL Krebs-HEPES solution, of the following 
composition (mM): NaC1 140, KC1 5.9, MgC12 1.2, 
CaC12 1, glucose 11, HEPES 10, at pH 7.2, at 37 °C. 
45CaZ+ uptake into chromaffin cells was studied by 
incubating the cells at 37 °C with 45CaClz at a final 
concentration of 5 jaCi mL-l in the presence of Krebs- 
HEPES (basal uptake), high K ÷ solution (Krebs- 
HEPES containing 70 mM KCI with isosmotic 
reduction of NaC1), or 100 jaM dimethylphenylpiper- 
azinium (DMPP) in Krebs-HEPES. This incubation 
was carried out during 1 min and at the end of this 
period the test medium was rapidly aspirated and the 
evoked 45Ca2+ uptake period was ended by adding 0.5 
mL of a cold Ca2+-free Krebs-HEPES containing 10 
mM LaC13. Finally, cells were washed five times more 
with 0.5 mL of Ca2+-free Krebs-HEPES containing 10 
mM LaC13 and 2 mM EGTA, at 15 s intervals. 
To measure radioactivity retained, cells were scraped 
with a plastic pipette tip while adding 0.5 mL 10% 
trichloroacetic acid, 3.5 mL scintillation fluid (Ready 
Micro, Beckman) was added and the samples counted 
in a Packard beta counter. Results are expressed as 
cpm 5 x 105 cells ~ or as % of Ca 2+ taken up by control 
cells. 
Electrophysiological recordings. DMPP-induced cur- 
rents and Ca 2+ currents through Ca 2+ channels were 
recorded using the whole-cell confguration of the 
patch-clamp technique. 34Cells plated on glass cover- 
slips were placed on an experimental chamber 
mounted on the stage of an inverted microscope. The 
chamber was continuously perfused with Tyrode 
solution containing (in mM): 137 NaCI, 1 MgC12. 2 
CaC12., 10 HEPES, titrated to pH 7.4 with NaOH. 
Recording electrodes (2-5 M~) were filled with a 
solution containing (in mM): 10 NaC1, 100 CsC1, 20 
TEA.C1, 5 Mg.ATP, 14 EGTA, 20 HEPES, 0.3 GTP, 
titrated to pH 7.2 with CsOH. Experiments were 
carried out at room temperature (23-25 °C). Extra- 
cellular solutions were changed rapidly by using a 
multi-barreled pipette with a common outlet placed 
within 100 jam from the cell under observation. Whole- 
cell recordings were made with a DAGAN 8900 ampli- 
fier. Data acquisition and analysis were performed 
using pClamp software. 
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